Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.89 USD
Change Today -0.07 / -3.57%
Volume 1.2M
CTIC On Other Exchanges
Symbol
Exchange
BrsaItaliana
NASDAQ CM
Frankfurt
As of 1:26 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$1.96
Previous Close
$1.96
Day High
$1.97
Day Low
$1.87
52 Week High
06/10/14 - $3.23
52 Week Low
03/26/15 - $1.77
Market Cap
340.7M
Average Volume 10 Days
1.1M
EPS TTM
$-0.54
Shares Outstanding
180.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

132 Employees
Last Reported Date: 03/12/15
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $553.5K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $551.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $585.0K
Compensation as of Fiscal Year 2013.

cti biopharma corp (CTIC) Key Developments

CTI BioPharma Corp. Amends Articles of Incorporation

The Amended and Restated Articles of Incorporation of CTI BioPharma Corp. became effective upon its filing with the Secretary of State of the State of Washington on March 23, 2015. The Amended and Restated Articles - restates the company's articles of incorporation to incorporate the several amendments to the articles that became effective between June 19, 2008 through February 27, 2015 and eliminates all references to the various series of preferred stock that were previously authorized but no longer have any shares outstanding.

CTI BioPharma Corp. Provides Earnings Guidance for the Year 2015

CTI BioPharma Corp. provided earnings guidance for the year 2015. The company expects total revenues for 2015 will be approximately $50 million to $55 million. The company expects that non-GAAP operating loss for 2015 will be approximately $75 million to $85 million, which excludes non-cash share-based compensation expense.

CTI BioPharma Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

CTI BioPharma Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's total revenues were $17,789,000 compared to $32,884,000 a year ago. Loss from operations was $39,374,000 compared to income from operations of $10,333,000 a year ago. Net loss attributable to common shareholders was $44,194,000 or $0.27 per basic and diluted share compared to net income attributable to common shareholders of $10,196,000 or $0.08 per basic and diluted share a year ago. Adjusted loss from operations was $36,200,000 compared to adjusted income from operations of $13,075,000 a year ago. The increase in operating loss for the fourth quarter 2014 compared to the same period in 2013 was primarily due to the acquired in process research and development associated with the acquisition of certain assets related to tosedostat from Chroma in 2014 in addition to the upfront payment received from BAXTER in 2013. For the year, the company's total revenues were $60,077,000 compared to $34,678,000 a year ago. Loss from operations was $86,233,000 compared to $41,526,000 a year ago. Net loss attributable to common shareholders was $95,992,000 or $0.65 per basic and diluted share compared to $49,643,000 or $0.43 per basic and diluted share a year ago. Adjusted loss from operations was $66,027,000 compared to $32,460,000 a year ago. Total revenues for the full year of 2014 included license and contract revenue of $53.2 million, which was primarily attributed to the following: $20 million development milestone payment from Baxter for completion of enrollment in PERSIST-1, recognition of $17.3 million from an upfront payment under the PIXUVRI collaboration agreement with Servier and $15 million in sales milestone related to TRISENOX and Teva Pharmaceuticals. The company expects that total revenues for 2015 will be approximately $50 million to $55 million. The company expects that non-GAAP operating loss for 2015 will be approximately $75 million to $85 million, which excludes non-cash share-based compensation expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $1.89 USD -0.07

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $2.92 USD -0.045
Cytokinetics Inc $6.80 USD -0.45
Navidea Biopharmaceuticals Inc $1.49 USD 0.00
Progenics Pharmaceuticals Inc $5.67 USD -0.36
Rigel Pharmaceuticals Inc $4.57 USD -0.305
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.